Do analysts rate NVNO or VVOS?

Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,717.00%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than enVVeno Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media favor NVNO or VVOS?

In the previous week, Vivos Therapeutics had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.51 beat Vivos Therapeutics' score of 0.38 indicating that enVVeno Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enVVeno Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ICCM or VVOS?

In the previous week, IceCure Medical had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for IceCure Medical and 2 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.38 beat IceCure Medical's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IceCure Medical 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INBS or VVOS?

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,717.00%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Intelligent Bio Solutions. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to VVOS or MBAI?

In the previous week, MBody AI had 6 more articles in the media than Vivos Therapeutics. MarketBeat recorded 8 mentions for MBody AI and 2 mentions for Vivos Therapeutics. MBody AI's average media sentiment score of 1.00 beat Vivos Therapeutics' score of 0.38 indicating that MBody AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBody AI 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VVOS or AEMD?

In the previous week, Vivos Therapeutics had 1 more articles in the media than Aethlon Medical. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Aethlon Medical. Aethlon Medical's average media sentiment score of 0.75 beat Vivos Therapeutics' score of 0.38 indicating that Aethlon Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aethlon Medical 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.15 +0.00 (+1.52%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$0.16 +0.00 (+0.58%)

As of 09:02 AM Eastern

Compare

VVOS vs. NVNO, ICCM, INBS, MBAI, and AEMD

Should you buy Vivos Therapeutics stock or one of its competitors? Vivos Therapeutics's main competitors and comparable companies include enVVeno Medical (NVNO), IceCure Medical (ICCM), Intelligent Bio Solutions (INBS), Check-Cap (MBAI), and Aethlon Medical (AEMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Vivos Therapeutics compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

enVVeno Medical has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.11, suggesting that its stock price is 511% more volatile than the broader market.

Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,717.00%. Given Vivos Therapeutics' higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than enVVeno Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

34.7% of enVVeno Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 15.0% of enVVeno Medical shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Vivos Therapeutics had 1 more articles in the media than enVVeno Medical. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.51 beat Vivos Therapeutics' score of 0.38 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enVVeno Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

enVVeno Medical has higher earnings, but lower revenue than Vivos Therapeutics. enVVeno Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A

enVVeno Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. enVVeno Medical's return on equity of -62.28% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

Summary

enVVeno Medical beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to IceCure Medical?

IceCure Medical (NASDAQ:ICCM) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, IceCure Medical had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for IceCure Medical and 2 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.38 beat IceCure Medical's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IceCure Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.11, meaning that its share price is 511% more volatile than the broader market.

Vivos Therapeutics has a net margin of -122.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IceCure Medical	-427.67%	-174.26%	-112.58%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

IceCure Medical presently has a consensus target price of $52.50, indicating a potential upside of 3,309.09%. Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 1,717.00%. Given IceCure Medical's higher probable upside, equities analysts clearly believe IceCure Medical is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 2.4% of IceCure Medical shares are held by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

IceCure Medical has higher earnings, but lower revenue than Vivos Therapeutics. IceCure Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IceCure Medical	$3.38M	1.56	-$15.06M	-$8.52	N/A
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A

Summary

Vivos Therapeutics beats IceCure Medical on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Intelligent Bio Solutions has a beta of 4.31, indicating that its stock price is 331% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.11, indicating that its stock price is 511% more volatile than the broader market.

In the previous week, Vivos Therapeutics had 2 more articles in the media than Intelligent Bio Solutions. MarketBeat recorded 2 mentions for Vivos Therapeutics and 0 mentions for Intelligent Bio Solutions. Vivos Therapeutics' average media sentiment score of 0.38 beat Intelligent Bio Solutions' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Intelligent Bio Solutions	Neutral
Vivos Therapeutics	Neutral

Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 1,717.00%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Intelligent Bio Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Intelligent Bio Solutions has higher earnings, but lower revenue than Vivos Therapeutics. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.31	-$12.43M	-$9.02	N/A
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A

Vivos Therapeutics has a net margin of -122.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%

33.0% of Intelligent Bio Solutions shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 1.3% of Intelligent Bio Solutions shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Vivos Therapeutics beats Intelligent Bio Solutions on 11 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to MBody AI?

Vivos Therapeutics (NASDAQ:VVOS) and MBody AI (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

In the previous week, MBody AI had 6 more articles in the media than Vivos Therapeutics. MarketBeat recorded 8 mentions for MBody AI and 2 mentions for Vivos Therapeutics. MBody AI's average media sentiment score of 1.00 beat Vivos Therapeutics' score of 0.38 indicating that MBody AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBody AI	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 1,717.00%. MBody AI has a consensus target price of $10.00, indicating a potential upside of 226.80%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Vivos Therapeutics is more favorable than MBody AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MBody AI has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. MBody AI's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
MBody AI	N/A	N/A	N/A

Vivos Therapeutics has a beta of 6.11, suggesting that its share price is 511% more volatile than the broader market. Comparatively, MBody AI has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

MBody AI has lower revenue, but higher earnings than Vivos Therapeutics. MBody AI is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A
MBody AI	N/A	N/A	$4.14M	-$14.07	N/A

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 1.1% of MBody AI shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by insiders. Comparatively, 0.5% of MBody AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Vivos Therapeutics beats MBody AI on 9 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to Aethlon Medical?

Vivos Therapeutics (NASDAQ:VVOS) and Aethlon Medical (NASDAQ:AEMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Vivos Therapeutics had 1 more articles in the media than Aethlon Medical. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Aethlon Medical. Aethlon Medical's average media sentiment score of 0.75 beat Vivos Therapeutics' score of 0.38 indicating that Aethlon Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aethlon Medical	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aethlon Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -122.00%. Aethlon Medical's return on equity of -123.08% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Aethlon Medical	N/A	-123.08%	-99.28%

Vivos Therapeutics has a beta of 6.11, indicating that its share price is 511% more volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Vivos Therapeutics currently has a consensus target price of $2.80, indicating a potential upside of 1,717.00%. Aethlon Medical has a consensus target price of $1.50, indicating a potential downside of 77.03%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Aethlon Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 0.6% of Aethlon Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aethlon Medical has lower revenue, but higher earnings than Vivos Therapeutics. Aethlon Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.12	-$21.17M	-$1.90	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A

Summary

Vivos Therapeutics beats Aethlon Medical on 10 of the 15 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.14M	$5.44B	$7.15B	$13.32B
Dividend Yield	N/A	1.81%	2.54%	17.38%
P/E Ratio	-0.08	25.76	274.34	26.21
Price / Sales	0.10	69.26	599.96	87.34
Price / Cash	N/A	32.73	27.22	34.70
Price / Book	-0.96	6.04	11.07	6.40
Net Income	-$21.17M	$146.97M	$3.49B	$381.07M
7 Day Performance	2.39%	-0.38%	-1.37%	-0.30%
1 Month Performance	-17.33%	-4.21%	-6.03%	-4.53%
1 Year Performance	-95.26%	2.13%	7.25%	1.62%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	2.507 of 5 stars	$0.15 +1.5%	$2.80 +1,717.0%	-95.2%	$2.14M	$20.90M	N/A	268	Positive News Gap Up
NVNO enVVeno Medical	1.3337 of 5 stars	$9.11 +5.5%	N/A	-76.4%	$6.33M	N/A	N/A	33	Positive News
ICCM IceCure Medical	2.5094 of 5 stars	$1.76 +10.6%	$52.50 +2,886.3%	-94.7%	$6.06M	$3.38M	N/A	66	News Coverage Positive News Gap Up
INBS Intelligent Bio Solutions	0.6843 of 5 stars	$1.71 +4.9%	N/A	-85.7%	$5.68M	$4.22M	N/A	10
MBAI Check-Cap	3.2899 of 5 stars	$3.50 -13.1%	$10.00 +186.1%	N/A	$4.85M	N/A	N/A	85	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. NVNO, ICCM, INBS, MBAI, and AEMD

How does Vivos Therapeutics compare to enVVeno Medical?

Summary

How does Vivos Therapeutics compare to IceCure Medical?

Summary

How does Vivos Therapeutics compare to Intelligent Bio Solutions?

Summary

How does Vivos Therapeutics compare to MBody AI?

Summary

How does Vivos Therapeutics compare to Aethlon Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. NVNO, ICCM, INBS, MBAI, and AEMD

How does Vivos Therapeutics compare to enVVeno Medical?

Which has more risk and volatility, NVNO or VVOS?

Do analysts rate NVNO or VVOS?

Do institutionals and insiders believe in NVNO or VVOS?

Does the media favor NVNO or VVOS?

Which has better earnings and valuation, NVNO or VVOS?

Is NVNO or VVOS more profitable?

Summary

How does Vivos Therapeutics compare to IceCure Medical?

Does the media prefer ICCM or VVOS?

Which has more volatility & risk, ICCM or VVOS?

Is ICCM or VVOS more profitable?

Do analysts prefer ICCM or VVOS?

Do institutionals & insiders believe in ICCM or VVOS?

Which has better valuation & earnings, ICCM or VVOS?

Summary

How does Vivos Therapeutics compare to Intelligent Bio Solutions?

Which has more volatility and risk, INBS or VVOS?

Does the media prefer INBS or VVOS?

Do analysts prefer INBS or VVOS?

Which has preferable valuation & earnings, INBS or VVOS?

Is INBS or VVOS more profitable?

Do institutionals and insiders hold more shares of INBS or VVOS?

Summary

How does Vivos Therapeutics compare to MBody AI?

Does the media refer more to VVOS or MBAI?

Do analysts prefer VVOS or MBAI?

Is VVOS or MBAI more profitable?

Which has more risk & volatility, VVOS or MBAI?

Which has higher valuation and earnings, VVOS or MBAI?

Do insiders and institutionals hold more shares of VVOS or MBAI?

Summary

How does Vivos Therapeutics compare to Aethlon Medical?

Does the media favor VVOS or AEMD?

Is VVOS or AEMD more profitable?

Which has more volatility and risk, VVOS or AEMD?

Do analysts rate VVOS or AEMD?

Do institutionals and insiders believe in VVOS or AEMD?

Which has higher earnings and valuation, VVOS or AEMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools